Abstract
This study was undertaken to determine the prevalence of female genital Aspergillus infections. Additionally, the study explored whether genital Aspergillus infections were associated with Aspergillus infections elsewhere (e.g., pulmonary, cardiac, orthopedic, or ophthalmologic). Between October 2005 and October 2007 vulvovaginal fungal cultures were performed for all patients seen in the Vulvar Disorders Center at the Good Samaritan Hospital (Cincinnati, OH) and similarly at Wright State Medical School Department of Obstetrics and Gynecology (Dayton, OH). Prospectively, any cultures showing Aspergillus species were segregated and a running list totaling 16 patients was maintained. The patients were all followed and examined at each subsequent visit for genital and extragenital disease. The patients responded to therapy with a culture-proven elimination of the fungus. Sporanox® (itraconozole; Janssen Pharmaceuticals, Titusville, NJ) 200 mg daily for 30 days proved to be the most objectively effective agent for fungus elimination. No systemic Aspergillus infections were observed during the follow-up period.
Get full access to this article
View all access options for this article.